Presentation is loading. Please wait.

Presentation is loading. Please wait.

P2Y12 receptor inhibitor therapy for secondary prevention of patients with stable coronary artery disease. P2Y12 receptor inhibitor therapy for secondary.

Published by怡锦 孔 Modified over 4 years ago

Similar presentations

Presentation on theme: "P2Y12 receptor inhibitor therapy for secondary prevention of patients with stable coronary artery disease. P2Y12 receptor inhibitor therapy for secondary."— Presentation transcript:

1 P2Y12 receptor inhibitor therapy for secondary prevention of patients with stable coronary artery disease. P2Y12 receptor inhibitor therapy for secondary prevention of patients with stable coronary artery disease. BMS, bare metal stent; CABG, coronary artery bypass graft surgery; CV, cardiovascular; DAPT, dual antiplatelet therapy; DES, drug-eluting stent; MI, myocardial infarction; PCI, percutaneous coronary intervention. Sophie Degrauwe et al. Open Heart 2017;4:e000651 ©2017 by British Cardiovascular Society

Download ppt "P2Y12 receptor inhibitor therapy for secondary prevention of patients with stable coronary artery disease. P2Y12 receptor inhibitor therapy for secondary."

Similar presentations

Bangalore S, et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308(13):1340-1349. ?

Bangalore S, et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308(13): ?
Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: AACVPR/ACC/AHA 2007 Performance Measures on Cardiac.

Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: AACVPR/ACC/AHA 2007 Performance Measures on Cardiac.
Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Fractional Flow Reserve Versus Angiography for Guiding.

Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Fractional Flow Reserve Versus Angiography for Guiding.
Date of download: 9/19/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Association of Public Reporting for Percutaneous.

Date of download: 9/19/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Association of Public Reporting for Percutaneous.
Subgroup analyses for mortality after treatment with coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI). LAD, left anterior.

Subgroup analyses for mortality after treatment with coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI). LAD, left anterior.
Algorithm for preoperative management of patients taking antiplatelet therapy. ACS, acute coronary syndrome; BMS, bare metal stent; DES, drug-eluting stent;

Algorithm for preoperative management of patients taking antiplatelet therapy. ACS, acute coronary syndrome; BMS, bare metal stent; DES, drug-eluting stent;
NORSTENT Trial design: Patients with obstructive coronary artery disease were randomized to a drug-eluting stent (DES) (n = 4,504) versus a bare-metal.

NORSTENT Trial design: Patients with obstructive coronary artery disease were randomized to a drug-eluting stent (DES) (n = 4,504) versus a bare-metal.
Robert A. Guyton, MD  The Annals of Thoracic Surgery 

Robert A. Guyton, MD  The Annals of Thoracic Surgery 
Copyright © 2013 American Medical Association. All rights reserved.

Copyright © 2013 American Medical Association. All rights reserved.
Figure 3 One-year adverse events (death, post-discharge myocardial infarction, revascularization) after PCI according to patients who (A) would not have.

Figure 3 One-year adverse events (death, post-discharge myocardial infarction, revascularization) after PCI according to patients who (A) would not have.
Comparison of Bare-Metal Stents and Drug-Eluting Stents in Coronary Ostial Lesions (from the National Heart, Lung, and Blood Institute Dynamic Registry) 

Comparison of Bare-Metal Stents and Drug-Eluting Stents in Coronary Ostial Lesions (from the National Heart, Lung, and Blood Institute Dynamic Registry) 
Ischaemic Heart Disease Acute Coronary Syndrome

Ischaemic Heart Disease Acute Coronary Syndrome
Glenn N. Levine et al. JACC 2016;68:

Glenn N. Levine et al. JACC 2016;68:
Achieving Long-Term Protection Post-MI

Achieving Long-Term Protection Post-MI
The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines  Alan D. Bell, MD, CCFP, André Roussin, MD, FRCPC,

The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines  Alan D. Bell, MD, CCFP, André Roussin, MD, FRCPC,
Glenn N. Levine et al. JACC 2016;68:

Glenn N. Levine et al. JACC 2016;68:
Manuel Caceres, MD, Darryl S. Weiman, MD, JD 

Manuel Caceres, MD, Darryl S. Weiman, MD, JD 
Robert A. Guyton, MD  The Annals of Thoracic Surgery 

Robert A. Guyton, MD  The Annals of Thoracic Surgery 
New antiplatelet drugs and new oral anticoagulants

New antiplatelet drugs and new oral anticoagulants
Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)

Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)

Similar presentations

Ads by Google